Neuropath Core

神经病核心

• 批准号: 10663237
• 负责人: Thomas J Montine
• 金额: $ 37.97万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663237
• 关键词: Acceleration; Action Research; Alzheimer' s Disease; Alzheimer' s disease model; Alzheimer’s disease biomarker; Animal Model; Area; Biological Markers; Biological Models; Biological Specimen Banks; Blood; Blood Vessels; Brain; Cerebrospinal Fluid; Cerebrum; Clinical; Collaborations; Collection; Communities; Consent; Consultations; DNA; DNA Repository; Data; Data Set; Development; Diagnosis; Diagnostic; Disease; Education; Evaluation; Fostering; Functional disorder; Goals; Human; Individual; Internet; Leadership; Liquid substance; Measurement; Measures; Mentors; Metabolic; Metabolic Diseases; Methods; Microscopy; Modeling; Molecular; Multi-Ethnic Study of Atherosclerosis; Neurodegenerative Disorders; Organoids; Participant; Pathologic; Pathology; Pathway interactions; Procedures; Protocols documentation; Research; Research Personnel; Resources; Risk; Rodent; Role; Sampling; Scientific Advances and Accomplishments; Senile Plaques; Specimen; Spinal Puncture; Technology; Therapeutic Research; Therapeutic Studies; Translational Research; Underrepresented Populations; Universities; Vascular Diseases; Washington; biological specimen archives; brain volume; clinical center; cohort; data management; distributed data; education research; endophenotype; forest; health disparity; innovation; inter-institutional; neuropathology; next generation; nonhuman primate; normal aging; novel; novel marker; operation; participant enrollment; programs; recruit; repository; sample collection; symposium; tau Proteins; therapeutic target; tissue biomarkers; translational model; vascular risk factor; virtual

Neuropathology Core – Project Summary The Neuropathology (NP) Core will provide unique resources to support the Wake Forest Alzheimer’s Disease Research Center (ADRC) focus on transitions from normal aging to MCI, AD, and related disorders, and the role of metabolic and vascular risk pathways in these transitions. The Core will foster innovative research in all areas relevant to AD. To accomplish these goals, the Core will provide state-of-the-art collection, storage, and distribution of brain and other biospecimens, establish neuropathological diagnoses of decedent Clinical Core (CC) participants, and provide resources and expertise for non-human primate (NHP) models for pivotal mechanistic and therapeutic research. The NP Core will also contribute to the ADRC theme of health disparities with a unique program focused on increasing brain donation from underrepresented groups (URGs). Through these activities, the NP Core will make impactful contributions to many National Alzheimer’s Project Act (NAPA) Research Milestones, such as supporting deep, longitudinal molecular endophenotyping of cohorts that include URGs (1A), data and sample sharing (3A, 4D), and development of the next generation of animal models (4A, B, C). The NP Core currently maintains a biospecimen repository of DNA, blood, and cerebrospinal fluid (CSF) from >1,100 well-characterized participants from the ADRC and its affiliated studies. In the coming cycle, we will continue to archive biospecimens from ADRC CC participants who have received careful metabolic and vascular characterization. DNA, CSF and blood will be provided to NCRAD, other consortia, and individual investigators. AD CSF biomarkers (Ab40, Ab42, tau, and p-tau181) are rigorously measured on all participants who undergo lumbar puncture (LP), and special expertise is available for blood and CSF biomarkers of metabolic and vascular disease. We continually assess scientific advances in identifying novel blood and CSF biomarkers of ADRD and will implement these as the field evolves. Further, human protocols for brain, blood and CSF collection have been applied to NHP models, creating a unique resource with which the AD research community can conduct pivotal translational research. In the past cycle, we demonstrated that our NHP model has neuropathologic changes similar to early AD such as amyloid plaques, AD-like CSF Ab42 profiles, cerebral hypometabolism, and reduced brain volumes. Consultation about NHP and other models (rodent, organoid) will be available. In summary, through careful clinico-pathologic analysis of well characterized cohorts, unique biospecimen repositories, and novel translational models, the NP Core will promote the WF ADRC themes, and provide an exceptional resource to investigate underlying mechanisms, novel biomarkers, and therapeutic targets that impact progression from normal aging to MCI and ADRD.

神经病理学核心 - 项目摘要 神经病理学（NP）核心将提供独特的资源来支持韦克森林阿尔茨海默氏症 疾病研究中心（ADRC）专注于从正常衰老到MCI，AD和相关疾病的过渡， 以及代谢和血管风险途径在这些过渡中的作用。核心将促进创新性 在与AD相关的所有领域进行研究。为了实现这些目标，核心将提供最先进的 大脑和其他生物测量的收集，存储和分布建立了神经病理学诊断 死者临床核心（CC）参与者，并为非人类灵长类动物（NHP）提供资源和专业知识 关键机械和治疗研究的模型。 NP核心也将为ADRC主题做出贡献 具有独特计划的健康差异的重点是增加代表性不足的大脑捐赠 组（urgs）。通过这些活动，NP核心将为许多国家做出有影响力的贡献 阿尔茨海默氏症的项目法（NAPA）研究里程碑，例如支持深，纵向分子 包括URG（1A），数据和样本共享（3A，4D）的同类型内型型和开发 下一代动物模型（4a，b，c）。 NP核心目前保持DNA，血液和脑脊液（CSF）的生物循环库。 从> 1,100名来自ADRC及其会员研究的特征良好的参与者。在接下来的周期中，我们 将继续从ADRC CC参与者那里归档生物测量，这些参与者接受了仔细的代谢和 血管表征。 DNA，CSF和血液将提供给NCRAD，其他财团和个人 调查人员。 AD CSF生物标志物（AB40，AB42，TAU和P-TAU181）对所有参与者进行了严格测量 谁经历了腰椎穿刺（LP），并且有特殊专业知识可用于血液和CSF生物标志物 代谢和血管疾病。我们不断评估鉴定新型血液和CSF方面的科学进步 ADRD的生物标志物，并将将其作为现场演变实施。此外，人类的大脑方案，血液方案 和CSF Collection已应用于NHP模型，创建了一个独特的资源 社区可以进行关键转化研究。在过去的周期中，我们证明了我们的NHP模型 具有与早期AD相似的神经病理学变化 低代谢和脑量减少。有关NHP和其他模型（啮齿动物，Organoid）的咨询 可用。 总而言之，通过精心特征的人群的仔细临床人群，独特的生物测试 存储库和新颖的翻译模型，NP Core将促进WF ADRC主题，并提供一个 研究基本机制，新型生物标志物和治疗靶标的特殊资源 从正常衰老到MCI和ADRD的影响进展。